Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5.
3
4-dihydroisocoumarin
P-glycoprotein
Pdr5
breast cancer resistance protein
cancer chemotherapy
multidrug resistance
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
09
2018
accepted:
01
04
2019
entrez:
2
5
2019
pubmed:
2
5
2019
medline:
2
5
2019
Statut:
epublish
Résumé
Multidrug resistance (MDR) in tumors and pathogens remains a major problem in the efficacious treatment of patients by reduction of therapy options and subsequent treatment failure. Various mechanisms are described to be involved in the development of MDR with overexpression of ATP-binding cassette (ABC) transporters reflecting the most extensively studied. These membrane transporters translocate a wide variety of substrates utilizing energy from ATP hydrolysis leading to decreased intracellular drug accumulation and impaired drug efficacy. One treatment strategy might be inhibition of transporter-mediated efflux by small molecules. Isocoumarins and 3,4-dihydroisocoumarins are a large group of natural products derived from various sources with great structural and functional variety, but have so far not been in the focus as potential MDR reversing agents. Thus, three natural products and nine novel 3,4-dihydroisocoumarins were designed and analyzed regarding cytotoxicity induction and inhibition of human ABC transporters P-glycoprotein (P-gp), multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP) in a variety of human cancer cell lines as well as the yeast ABC transporter Pdr5 in
Identifiants
pubmed: 31040786
doi: 10.3389/fphar.2019.00400
pmc: PMC6476959
doi:
Types de publication
Journal Article
Langues
eng
Pagination
400Références
Curr Infect Dis Rep. 2000 Oct;2(5):391-398
pubmed: 11095883
Blood. 2002 Aug 15;100(4):1224-32
pubmed: 12149202
J Biol Chem. 2002 Nov 29;277(48):46809-21
pubmed: 12244114
J Biol Chem. 2003 Dec 26;278(52):52629-40
pubmed: 14551217
J Comput Chem. 2004 Jan 30;25(2):238-50
pubmed: 14648622
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Org Lett. 2004 Jun 10;6(12):1951-4
pubmed: 15176791
J Pathol. 2005 Jan;205(2):275-92
pubmed: 15641020
Cancer Chemother Pharmacol. 2005 Aug;56(2):173-81
pubmed: 15824923
Cancer. 2005 Aug 15;104(4):682-91
pubmed: 15986399
Methods Enzymol. 2005;400:460-84
pubmed: 16399365
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
pubmed: 16518375
Bioorg Med Chem. 2006 Oct 15;14(20):6979-87
pubmed: 16824763
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
J Med Chem. 2006 Nov 2;49(22):6596-606
pubmed: 17064078
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5069-74
pubmed: 18356296
J Nat Prod. 2008 Jun;71(6):1082-4
pubmed: 18462007
BMC Cancer. 2009 Jul 20;9:242
pubmed: 19619277
Methods Mol Biol. 2010;596:47-76
pubmed: 19949920
ChemMedChem. 2010 Jun 7;5(6):811-22
pubmed: 20373322
Drug Metab Dispos. 2010 Aug;38(8):1371-80
pubmed: 20423956
J Chem Inf Model. 2011 Jan 24;51(1):69-82
pubmed: 21117705
ChemMedChem. 2011 Apr 4;6(4):713-24
pubmed: 21302361
J Med Chem. 2011 May 12;54(9):3153-62
pubmed: 21488686
J Biol Chem. 2011 Jul 29;286(30):26470-9
pubmed: 21665946
Curr Pharm Des. 2011;17(26):2793-802
pubmed: 21827403
Nucleic Acids Res. 2012 Jan;40(Database issue):D370-6
pubmed: 21890895
Bioorg Med Chem Lett. 2011 Oct 15;21(20):6112-5
pubmed: 21903387
Proteins. 2011 Oct;79(10):2794-812
pubmed: 21905107
Drug Resist Updat. 2012 Feb-Apr;15(1-2):98-105
pubmed: 22483810
Biochemistry. 2012 Jun 26;51(25):5125-41
pubmed: 22647192
Cell Host Microbe. 2012 Jun 14;11(6):654-63
pubmed: 22704625
Eur J Med Chem. 2012 Aug;54:413-22
pubmed: 22743241
Sci Transl Med. 2012 Dec 19;4(165):165rv13
pubmed: 23253612
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
F1000Prime Rep. 2013 Dec 03;5:51
pubmed: 24381727
J Biol Chem. 2014 May 30;289(22):15272-9
pubmed: 24733388
J Org Chem. 2014 May 16;79(10):4699-703
pubmed: 24745807
J Biol Chem. 2014 Nov 7;289(45):31397-410
pubmed: 25253691
Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):318-22
pubmed: 25446092
Anticancer Agents Med Chem. 2015;15(5):605-15
pubmed: 25584696
Biochemistry. 2015 Jul 21;54(28):4374-90
pubmed: 26125482
Eur J Med Chem. 2015 Aug 28;101:560-72
pubmed: 26197160
Bioorg Med Chem Lett. 2016 Jan 1;26(1):235-9
pubmed: 26586600
J Chem Theory Comput. 2011 Feb 8;7(2):525-37
pubmed: 26596171
J Chem Theory Comput. 2011 Jul 12;7(7):2284-95
pubmed: 26606496
J Nat Prod. 2016 Mar 25;79(3):629-61
pubmed: 26852623
Eur J Med Chem. 2016 Mar 23;111:103-13
pubmed: 26859070
Eur J Med Chem. 2016 Jun 30;116:290-317
pubmed: 27155563
J Nat Prod. 2016 Aug 26;79(8):2022-31
pubmed: 27441892
Eur J Med Chem. 2016 Nov 29;124:428-434
pubmed: 27597418
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Mol Pharm. 2017 Jan 3;14(1):135-146
pubmed: 28043125
Eur J Med Chem. 2017 Feb 15;127:577-585
pubmed: 28109950
Front Pharmacol. 2017 Jan 10;7:535
pubmed: 28119610
Bioorg Med Chem. 2017 Nov 15;25(22):6115-6125
pubmed: 28214230
Molecules. 2017 Mar 15;22(3):
pubmed: 28294992
Acta Pharm Sin B. 2017 Mar;7(2):119-136
pubmed: 28303218
Expert Opin Ther Targets. 2017 May;21(5):511-530
pubmed: 28335655
Curr Med Chem. 2017;24(30):3242-3253
pubmed: 28545374
Phytother Res. 2017 Oct;31(10):1529-1538
pubmed: 28752532
Methods Enzymol. 1988;157:513-28
pubmed: 2906715
Methods Enzymol. 1988;157:528-33
pubmed: 2906716
Biochim Biophys Acta Biomembr. 2018 Apr;1860(4):818-832
pubmed: 29097275
Int J Mol Sci. 2017 Nov 08;18(11):null
pubmed: 29117122
Fitoterapia. 2018 Mar;125:111-116
pubmed: 29289635
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E1973-E1982
pubmed: 29440498
J Nat Med. 2019 Jan;73(1):226-235
pubmed: 30066239
Am J Clin Oncol. 1995 Jun;18(3):251-6
pubmed: 7747714
J Biol Chem. 1994 Apr 29;269(17):12797-803
pubmed: 8175692
J Biol Chem. 1996 Dec 6;271(49):31543-8
pubmed: 8940170